Additional file 2 of Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

Additional file 2: Table S1. Cumulative incidence of immune-related and non-immune related adverse events of any grade, of grade 3–4 and of those leading to treatment discontinuation in patients with relapsed and refractory classical Hodgkin lymphoma treated with nivolumab monotherapy.